Australia markets close in 2 hours 49 minutes

Beximco Pharmaceuticals Limited (R2WA.SG)

Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
0.4200+0.0160 (+3.96%)
At close: 10:33AM CEST
Currency in EUR

Valuation measures4

Market cap (intra-day) 441.63M
Enterprise value 492.36M
Trailing P/E 4.05
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)0.50
Price/book (mrq)0.46
Enterprise value/revenue 0.01
Enterprise value/EBITDA 0.06

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-2.42%
S&P500 52-week change 324.49%
52-week high 30.5000
52-week low 30.3700
50-day moving average 30.4245
200-day moving average 30.4327

Share statistics

Avg vol (3-month) 3876
Avg vol (10-day) 31.2k
Shares outstanding 5446.11M
Implied shares outstanding 61.09B
Float 8297.32M
% held by insiders 10.00%
% held by institutions 11.72%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 40.03
Forward annual dividend yield 47.30%
Trailing annual dividend rate 33.50
Trailing annual dividend yield 3866.34%
5-year average dividend yield 44.06
Payout ratio 429.75%
Dividend date 3N/A
Ex-dividend date 410 Nov 2023
Last split factor 21.1:1
Last split date 323 Nov 2020

Financial highlights

Currency in BDT.

Fiscal year

Fiscal year ends 30 June 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 12.37%
Operating margin (ttm)17.20%

Management effectiveness

Return on assets (ttm)6.97%
Return on equity (ttm)10.99%

Income statement

Revenue (ttm)43.08B
Revenue per share (ttm)96.58
Quarterly revenue growth (yoy)15.00%
Gross profit (ttm)N/A
EBITDA 9.44B
Net income avi to common (ttm)5.33B
Diluted EPS (ttm)0.1000
Quarterly earnings growth (yoy)43.50%

Balance sheet

Total cash (mrq)1.36B
Total cash per share (mrq)3.05
Total debt (mrq)7.43B
Total debt/equity (mrq)14.73%
Current ratio (mrq)1.80
Book value per share (mrq)N/A

Cash flow statement

Operating cash flow (ttm)8.37B
Levered free cash flow (ttm)4.05B